## TXN: Texas Instruments Incorporated - XLK: Technology

### Executive Summary

No thesis match: MRS_20 1.3% below STRENGTH zone (4.0-10.0%); PEG 1.52 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.4% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($169.78)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Texas Instruments (TXN) Stock Today (Dec. 22, 2025): Sherman Fab Momentum Meets a Split Wall Street**
- Source: ts2.tech | 20251222T183555 | Neutral | Relevance: 100%
- Texas Instruments (TXN) is experiencing a modest rebound, balancing a major U.S. manufacturing milestone with questions about demand recovery and margins. The company's new Sherman SM1 fab has begun production, a significant step in its $60+ billion U.S. manufacturing plan, while analysts remain split on its short-term profitability due to capacity building ahead of demand. Investors are keenly watching industrial demand, gross margins, and the pace of the Sherman fab's ramp-up ahead of the next earnings report in late January 2026.

**2. Legacy Wealth Asset Management LLC Grows Stock Position in Texas Instruments Incorporated $TXN**
- Source: MarketBeat | 20251222T120846 | Neutral | Relevance: 100%
- Legacy Wealth Asset Management LLC significantly increased its stake in Texas Instruments Incorporated (NASDAQ:TXN) by 119.2% in Q3, now holding 10,510 shares valued at approximately $1.931 million. Other institutional investors like Vanguard Group Inc., Jennison Associates LLC, and Invesco Ltd. also boosted their positions in the semiconductor company. Despite insider selling by a VP and a director, the stock currently holds a consensus "Hold" rating from analysts with an average target price of $191.49.

**3. Texas Instruments (TXN) Stock: Latest News, Analyst Forecasts, and What to Watch Before the Market Opens on Dec. 22, 2025**
- Source: ts2.tech | 20251222T041728 | Neutral | Relevance: 100%
- This article provides a comprehensive overview of Texas Instruments (TXN) stock ahead of the Dec. 22, 2025, market open. It highlights key factors such as the start of production at its new Sherman fab, the impact of tariffs and trade policy, a review of Q3 2025 earnings and Q4 guidance, dividend information, and diverse analyst forecasts. The article emphasizes the ongoing debate between long-term manufacturing strength and near-term market caution for TXN investors, also touching on potential headline risks from lawsuits.

**4. Texas Instruments Stock (NASDAQ: TXN) on Dec. 20, 2025: Sherman Fab Starts Production, Analysts Split on the 2026 Outlook**
- Source: ts2.tech | 20251220T210825 | Neutral | Relevance: 100%
- Texas Instruments' new 300mm Sherman fab has officially begun production, marking a significant U.S. manufacturing milestone. However, analysts are divided on the company's 2026 outlook, with some raising concerns about potential earnings drag from heavy investment while others maintain a more positive long-term view. The debate centers on how TI's aggressive capacity buildout and inventory management will impact its margins and cash flow amidst varying demand recovery scenarios.

**5. Stolper Co Buys New Stake in Texas Instruments Incorporated $TXN**
- Source: MarketBeat | 20251221T120851 | Neutral | Relevance: 100%
- Stolper Co initiated a new position in Texas Instruments (TXN) by purchasing 11,896 shares valued at approximately $2.19 million in Q3. This move comes as other major institutional investors like Vanguard, State Street, and Norges Bank have also increased their stakes in the semiconductor company. Despite several analysts lowering price targets in October, the consensus rating for Texas Instruments remains "Hold" with a target price of $191.49.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Truist Securiti | $195 | $175 | +11% |
| 2025-12-15 | Goldman Sachs | $156 | $200 | -22% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Truist Securiti | main | Hold |
| 2025-12-15 | Goldman Sachs | down | Sell |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.53M) |
| Sells | 4 ($0.52M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 10.6% (+1.1%)
- Blackrock Inc.: 8.5% (+0.1%)
- JPMORGAN CHASE & CO: 6.0% (+80.5%)
- State Street Corpora: 4.8% (+0.5%)
- Charles Schwab Inves: 2.5% (+3.9%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- New product launch cycle could drive revenue acceleration.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.52 elevated, pricing in significant growth expectations. Forward P/E 29.1x stretched relative to 12% growth. Quality metrics strong (ROE 30%, ROA 11%, margin 29%). Balance sheet: strong liquidity (4.5x). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $162.6B |
| Beta | 0.99 |
| 52W Range | $139.95 - $221.69 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.52 |
| Forward P/E | 29.1 |
| Current P/E | 32.6 |
| YoY Growth | 12.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.7% to 1.3% (-2.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.7pp (needs >4.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.98x), long-term trend not supportive. RSI neutral at 59. Elevated volume (1.5x 20MA), institutional activity likely. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.32% (CS: 61) | Neutral |
| RSI_14 | 58.9 | Neutral |
| MACD Histogram | -0.23 | Bearish |
| vs SMA20 | 1.019x | Above |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 0.985x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $178.82
- **Stop Loss:** $169.78 (5.1% risk)
- **Target:** $187.86 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 132
- **Position Value:** $23,604.24
- **Portfolio %:** 23.60%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-01-20 (Est: $1.31)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.49 | $1.48 | -0.4% |
| 2025Q2 | $1.33 | $1.41 | +5.8% |
| 2025Q1 | $1.06 | $1.28 | +20.2% |
| 2024Q4 | $1.20 | $1.30 | +8.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*